Apeiron Biologics AG licensed its lead program APN01, a recombinant form of human angiotensin converting enzyme 2 (ACE2), to London-based GlaxoSmithKline plc in a deal valued at up to €236 million (US$329.4 million). (BioWorld International) Read More
